The mean arterial pressure (MAP) usually serves as an expression of blood pressure in patients on chronic haemodialysis (PCHD), instead of using solely systolic or diastolic pressure. Pulse pressure (PP) has been recognized as an important correlate of mortality in PCHD. We conducted this study in order to demonstrate clinical and biochemical determinants and variability of predialysis and postdialysis MAP and PP values. A total of 136 single haemodialysis (HD) treatments in 23 subjects (PCHD, 11 male and 12 female patients) were processed during 15 months. MAP before HD was in negative correlation with haemoglobin (Po0.001) and body mass index (BMI) (Po0.001), and in positive correlation with weekly erythropoietin dosage (P ¼ 0.017). MAP after HD was in negative correlation with haemoglobin (Po0.001), ultrafiltration per HD (P ¼ 0.015), and BMI (P ¼ 0.001), and in positive correlation with weekly erythropoietin dosage (P ¼ 0.003). PP before HD was in negative correlation with parathyroid hormone (PTH) level (P ¼ 0.020), haemoglobin (Po0.001), ultrafiltration per HD (P ¼ 0.001), and years on the chronic HD treatment (P ¼ 0.001), and in positive correlation with weekly erythropoietin dosage (Po0.001) and age (Po0.001). PP after HD was in significant negative correlation with PTH (P ¼ 0.015), haemoglobin (P ¼ 0.005), ultrafiltration per HD (Po0.001), BMI (P ¼ 0.003), and in positive correlation with weekly erythropoietin dosage (Po0.001) and age (P ¼ 0.004). Multiple regression analyses unveiled the strongest and negative correlations between MAP before HD and BMI (b ¼ À0.37, P ¼ 0.01); MAP after HD and haemoglobin (b ¼ À0.36, P ¼ 0.01); PP after HD and ultrafiltration/body weight ratio (b ¼ À0.41, Po0.001).
The mean arterial pressure (MAP) usually serves as an expression of blood pressure in patients on chronic haemodialysis (PCHD), instead of using solely systolic or diastolic pressure. Pulse pressure (PP) has been recognized as an important correlate of mortality in PCHD. We conducted this study in order to demonstrate clinical and biochemical determinants and variability of predialysis and postdialysis MAP and PP values. A total of 136 single haemodialysis (HD) treatments in 23 subjects (PCHD, 11 male and 12 female patients) were processed during 15 months. MAP before HD was in negative correlation with haemoglobin (Po0.001) and body mass index (BMI) (Po0.001), and in positive correlation with weekly erythropoietin dosage (P ¼ 0.017). MAP after HD was in negative correlation with haemoglobin (Po0.001), ultrafiltration per HD (P ¼ 0.015), and BMI (P ¼ 0.001), and in positive correlation with weekly erythropoietin dosage (P ¼ 0.003). PP before HD was in negative correlation with parathyroid hormone (PTH) level (P ¼ 0.020), haemoglobin (Po0.001), ultrafiltration per HD (P ¼ 0.001), and years on the chronic HD treatment (P ¼ 0.001), and in positive correlation with weekly erythropoietin dosage (Po0.001) and age (Po0.001). PP after HD was in significant negative correlation with PTH (P ¼ 0.015), haemoglobin (P ¼ 0.005), ultrafiltration per HD (Po0.001), BMI (P ¼ 0.003), and in positive correlation with weekly erythropoietin dosage (Po0.001) and age (P ¼ 0.004). Multiple regression analyses unveiled the strongest and negative correlations between MAP before HD and BMI (b ¼ À0.37, P ¼ 0.01); MAP after HD and haemoglobin (b ¼ À0.36, P ¼ 0.01); PP after HD and ultrafiltration/body weight ratio (b ¼ À0.41, Po0.001). The strongest and positive correlation was found between PP before HD and erythropoietin dosage per week (b ¼ 0.51, Po0.001).
In conclusion, our findings support the assumption that PP and MAP are associated with different clinical parameters. PP values have advantages as the method of blood pressure expression.
Introduction
Cardiovascular disease is the leading cause of morbidity and mortality in end-stage renal disease. 1 Hypertension is very common and contributes to the high cardiovascular morbidity in patients undergoing chronic haemodialysis therapy (PCHD). 2 While high blood pressure (BP) has been documented to impact several outcomes of cardiovascular disease, whether hypertension is an independent risk factor for mortality in this population is not clear. 3 Although increased BP is associated with adverse outcomes in the general population, elevated BP is associated with decreased mortality in patients with end-stage renal disease undergoing maintenance haemodialysis (HD). 4 Zager et al 5 suggest the presence of a 'U' curve relation between postdialysis systolic BP and cardiovascular mortality in HD patients. Low predialysis systolic BP (o110 mmHg) and low predialysis diastolic BP (o70 mmHg) are associated with increased mortality, primarily because of severe congestive heart failure or coronary artery disease. 5 Optimal BP in dialysis patients is not different from recommendations for the general population, even though definite evidence is not yet available.
Definition and expression of hypertension in PCHD are still under debate. Predialysis systolic and diastolic BPs are of particular importance. Interdialytic ambulatory blood pressure monitoring may help to determine if the patient is in fact hypertensive. 6 The mean arterial pressure (MAP) is often used as an expression of BP in HD patients, instead of using solely systolic or diastolic BP.
Investigations in the general population have demonstrated the predictive utility of pulse pressure (PP) (systolic-diastolic BP), a measure reflecting the pulsatile nature of the cardiac cycle. 7 Recent recognition of PP as an important correlate of mortality in patients receiving dialysis highlights the need to investigate the relation between PP, MAP and clinical outcomes in patients with end-stage renal disease. 8 PP and MAP are associated with different clinical parameters in PCHD. 9 There are no reports of the clinical and biochemical determinants of both predialysis and postdialysis MAP and PP values in dialysis populations.
We conducted this study in order to demonstrate the clinical and biochemical determinants and variability of predialysis and postdialysis MAP and PP values during a 15-month period in a group of PCHD.
Subjects and methods
Study subjects were 23 anuric PCHD (11 male and 12 female subjects) on three-time-per-week dialysis regimen with a history of chronic HD treatment for at least 1 year (mean HD treatment period was 5.09 7 3.59 years). A total of 15 subjects suffered from chronic glomerulonephritis, five from chronic pyelonephritis, and three had diabetic nephropathy.
Overall study time was 15 months. Assessments were undertaken at the beginning of the study and at 3 month intervals; in all, six measurements per subject were conducted. In total, 136 single HD treatments in 23 subjects were processed. The HD treatments were categorized into three groups: HDs in the subjects treated with peroral antihypertensives (group 1), HDs in the subject without antihypertensive medication (group 2), and HDs with intradialytic hypotension (MAP during dialysis o70 mmHg) with at least one staff intervention during treatment (group 3).
Antihypertensive drugs used were ACE inhibitors (three subjects), calcium antagonists (two subjects) and beta blockers (two subjects).
Primary outcome measures for every single observed HD were systolic and diastolic BP before and after HD treatment (mmHg), blood concentration of urea before and after HD (mmol/l), haemodialysis (g/ l), calcium, phosphorus (mmol/l), total protein and albumin in serum (g/l), alkaline phosphatase (IU/l), parathyroid hormone (PTH) (ng/l), creatinine (mmol/ l), total cholesterol, low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglycerides (mmol/l). Additionally, subject age and years on chronic dialysis treatment, HD duration (h), ultrafiltration (l), dry body mass (kg), and heparinization (IU) per single dialysis, and erythropoietin dosage (IU) per week were observed.
Secondary outcome measures were single-dialysis efficacy Kt/V calculated according to Daugirdas 10 second-generation formula, normalized protein catabolic rate (nPCR) (g/kg/day), 11 dry body mass index (BMI) (kg/m 2 ), predialysis and postdialysis MAP calculated as (systolic +2 diastolic BP)/3 (mmHg), predialysis and postdialysis PP computed as (systolicÀdiastolic BP) (mmHg), difference between predialysis and postdialysis MAP (delta MAP, mmHg), difference between predialysis and postdialysis PP (delta MAP, mmHg), and ultrafiltration volume/ dry body mass (UF/W) ratio (l/kg).
The duration of single HD treatment was 3.5-5 h, mean heparinization dose was 4950 7 1282 IU, temperature of the dialysis bath was 35.5-36.61C, and the dialysis bath consisted of bicarbonate 32À35 mmol/l, sodium 138-145 mmol/l, potassium 2 mmol/l, and calcium 1.25-1.75 mmol/l. The subjects were dialysed on low flux polysulphone dialysers F6 and F8 (Fresenius, Bad Homburg, Germany). All subjects had Cimino fistula as blood access.
Blood was taken just before connecting subjects on the dialysis machine and before giving heparin. Postdialysis blood sample (for postdialysis blood urea concentration) was taken with a blood pump reduced to 50 ml/min and then after 2 min, blood specimen was taken from the arterial part of the dialysis system.
No subject dropped out from the study. No subject was transfused. During the study period, medication and dialysis conditions for the same subject were unchanged.
BP was measured with mercury column sphygmomanometer by a trained clinician, just before beginning of the HD treatment and just after the end of the same dialysis treatment in recumbent subject. Disappearance of bruits (Korotkoff phase V) identified diastolic BP. Ultrafiltration was measured volumetrically on the dialysis machine.
Haematological and biochemical parameters were measured using routine laboratory methods. Triglycerides, total cholesterol, and HDL-cholesterol were analysed with enzymatic kits, and LDL-cholesterol was calculated according to Friedewald's equation. 12 PTH was measured with radioimmunosorbent assay (RAI).
The results were expressed as arithmetic mean 7 standard deviation. Normality of distribution was tested with the Shapiro-Wilk's W test. Differences between two dialysis groups were calculated by Student's t-test for independent data. Outcome differences between three dialysis groups were calculated by one-way multivariate analysis of variance (MANOVA) with Bonferroni tests for intergroup differences. Correlations between variables were tested by Pearson correlation coefficients. In order to determine variable(s) with the most powerful influence on MAP and PP before and after dialysis, we performed four forward stepwise multiple regression analyses.
A P-value of less than 0.05 was considered to be statistically significant.
Results
Data from 136 single dialysis treatments were processed: 40 dialyses were in group 1, 59 dialyses in group 2 and 37 dialyses were in group 3.
Overall study predialysis and postdialysis MAPs and PPs differed significantly (101. 24 Table 1 . In group 1, we did not find difference between postdialysis and predialysis PP values, but we found difference between postdialysis and predialysis MAP values (P ¼ 0.009). In group 3, we found difference neither between postdialysis vs predialysis MAP nor postdialysis vs predialysis PP values. On the contrary, in group 2 we demonstrated significant differences between both postdialysis vs predialysis MAP and postdialysis vs predialysis PP values (Po0.001, P ¼ 0.004).
We also tested differences between HD MAPs and PPs in male and female subjects. Those differences are shown in Table 2 . We found gender differences in MAP before HD and MAP after HD (P ¼ 0.02, and P ¼ 0.03), but not in PP before HD or PP after HD.
One-way MANOVA revealed significant differences among the HD groups in alkaline phosphatase (P ¼ 0.021), HDL-cholesterol (P ¼ 0.035), BMI (P ¼ 0.001), MAP before HD (Po0.001), MAP after HD (P ¼ 0.008), and PP before HD (P ¼ 0.020). Outcomes differences between the groups are shown on In order to show time-dependent changes in MAP, PP, and ultrafiltration; we performed one-way MANOVA with sampling time as an independent variable. We did not find time-dependent significant differences in MAP before HD, MAP after HD, PP before HD, PP after HD, delta MAP, and delta PP (P40.05), but we found significant differences in ultrafiltration (P ¼ 0.023) and UF/W ratio (P ¼ 0.003) with respect to the time sequence. The timedependent changes of the variables are depicted in the Figure 1 .
We also performed Pearson's correlations between variables through all 136 HDs. MAP before HD was in negative correlation with haemoglobin (r ¼ À0.293, Po0.001), alkaline phosphatase concentration (r ¼ À0.218, P ¼ 0.006), BMI (r ¼ À0.355, Po0.001), and years on the chronic HD treatment (r ¼ À0.229, P ¼ 0.004), and in positive correlation with total serum proteins (r ¼ 0.268, P ¼ 0.001) and weekly erythropoietin dosage (r ¼ 0.183, P ¼ 0.017). MAP after HD was in significant negative correlation with haemoglobin (r ¼ À0.361, Po0.001), ultrafiltration per HD (r ¼ À0.186, P ¼ 0.015), BMI (r ¼ À0.298, P ¼ 0.001), and years on the chronic HD treatment (r ¼ À0.220, P ¼ 0.005), and in positive correlation with weekly erythropoietin dosage (r ¼ 0.238, In order to determine variable(s) with the most powerful influence on MAP and PP values before and after dialysis, we performed four forward stepwise multiple regression analyses with MAP and PP values before and after dialysis as dependent variables and haemoglobin, calcium, phosphorus, albumin in serum, PTH, age, years on chronic dialysis treatment, HD duration, ultrafiltration, heparinization per dialysis, erythropoietin dosage per week, single-dialysis efficacy Kt/V (Daugirdas second-generation), nPCR, dry BMI, and UF/W ratio as independent variables in the regression models. The results of the regressions are shown in Table 4 . The strongest and negative correlations were found between MAP before HD and BMI (b ¼ À0. 
Discussion
Our data demonstrate the differences in predictors of pre/postdialysis MAP and PP values in PCHD. This confirmed our assumption of different meaning of MAP and PP values in BP consideration of dialysis patients. We also revealed differences in We also demonstrated gender differences in MAP before HD and MAP after HD, but we could not demonstrate differences in PP before HD or PP after HD. The antihypertensive effects of oestrogens in female have been well demonstrated. oestrogens have vasodilatory effects on the endothelium, and inhibit vascular smooth muscle cell growth and constriction. 13 We conclude that oestrogens in dialysis female patients affect only MAP (predialysis and postdialysis difference), but do not affect PP.
When we observed the overall study group, we found negative correlation between haemoglobin concentration and both pre/postdialysis MAP and PP values. Furthermore, multiple regression analysis unveiled the strongest negative influence of the haemoglobin concentration on the MAP after HD. Although Rocco et al 14 demonstrated that lower haematocrit is associated with higher pre-and postdialysis systolic BP, this influence of haemoglobin on BP in HD patients was never fully explained. Regression of left ventricular hypertrophy with improvement of renal anaemia could be an explanation of this observation. 15 On the contrary, erythropoietin weekly dosage was in positive correlation with pre/postdialysis BP (both MAP and PP, but with higher correlation coefficient with PP values). Multiple regression analysis also demonstrated the strongest positive influence of weekly erythropoietin dosage on the PP before HD. The influence of erythropoietin on BP increment in renal failure patient is already known. Erythropoietin-induced rise in blood pressure may partly be related to the enhancement of nitric oxide (NO) production in PCHD. 16 We demonstrated that BMI was in negative correlation with pre/postdialysis MAP and PP after dialysis. Furthermore, multiple regression analysis unveiled the strongest negative influence of the BMI on the MAP before HD. Lower BMI may indicate malnutrition, the condition of PCHD closely related to atherosclerosis because of similar pathogenesis, which include proinflammatory cytokines. 17 Associated action of proinflammatory cytokines in PCHD lead to malnutrition, inflammation, and atherosclerosis or MIA syndrome. 18 Atherosclerosis could be a link between lower BMI (malnutrition) and higher MAP before HD.
Number of years on chronic haemodialysis treatment was in negative correlation with both pre/ postdialysis PP and MAP. The improvement in MAP and PP with duration of dialysis might be the result of better survival of the patients with the healthiest blood vessels. 19 Furthermore, Level et al 20 demonstrated that arterial compliance is reduced in chronic HD patients, and dependent on the previous duration of HD therapy, which could explain lower diastolic pressure and therefore decreased MAP in patients who had been treated by chronic dialysis for longest.
Age was in positive correlation with pre/postdialysis PP values, but was not with MAP. The positive influence of aging on PP could be attributed to the vascular stiffness and reduced arterial compliance in older subjects. 21 PTH and phosphorus concentration had negative influence on pre/postdialysis PP values, but did not influence MAP values. Clinical studies have provided evidence that raised calcium-phosphate products led to myocardial and valve calcification and to cardiac dysfunction, and reduction in blood level of PTH in uraemic patients by parathyroidectomy led to a significant improvement in cardiac function. 22 Elevated PTH levels and phosphorus concentration also lead to increased vascular calcification, which could explain the increase in PP values. 23 It is also possible that the association between raised PTH and phosphorus, and lower PP represents survival of those patients with the healthiest blood vessels for the longest period, while PTH and phosphorus concentration continue to rise in parallel with the duration of dialysis. 24 The impact of ultrafiltration and volume control on HD BP is a well-known fact. 25 Although hypertension in the HD patient population is multifactorial, volume overload is a main factor in development of hypertension in HD patients. 26 Prakash et al 27 30 also concluded that interdialytic fluid load does not result in higher BP in HD patients. Expansion of extracellular fluid volume is the major pathophysiologic mechanism for the development of hypertension in these patients; however, alterations in other humoral mechanisms (especially NO, endothelin 1, and renin imbalance) also play a significant role. [31] [32] [33] We revealed influ-ence of UF/W ratio only on the PP before and after HD, but there was no correlation between UF/W and pre/postdialysis MAP values. When we observed time-dependent variations of MAP, PP ultrafiltration, and UF/W ratio during the study period, we could not demonstrate time-dependent differences in MAPs and PPs, but we displayed significant differences in UF/W ratio and ultrafiltration per dialysis in respect of sampling time through the study. Argiles et al 34 proved that in patients with end-stage renal disease treated with HD, BP varies seasonally, with higher values in winter and lower values in summer; a similar pattern is seen in essential hypertensives. 35 We could not find timedependent significant differences in MAPs and PPs in 15 months study duration.
In Figure 1 , the time-dependent curves of MAP, PP, ultrafiltration, and UF/W ratio are represented. Although PP values did not display time-dependent differences, in Figure 1 is seen that predialysis PP curve has the same shape as ultrafiltration and UF/ W time-dependent curves. Additionally, multiple regression analysis revealed that UF/W ratio had the most powerful influence on PP after dialysis values. Although ultrafiltration and volume overload was important as the factor having greatest influence on BP control in PCHD, we must conclude that ultrafiltration and volume overload impact only PP, especially ultrafiltration rate is related with PP postdialysis values.
Finally, these findings support our assumption that PP and MAP values are associated with different clinical parameters. MAP and PP values in haemodialysed patients must be observed separately because the MAP and PP values represent different expression of BP in PCHD. PP values in PCHD are an index of myocardial function, vascular compliance and volume overload, and have some advantages as the method of BP expression in PCHD. We found that PP values were not as gender dependent as MAP values. Consequently, diagnosis and treatment of BP in PCHD must be considered in respect of pre/postdialysis MAP and especially PP values, not just depending on pre/postdialysis systolic and diastolic pressure values. 36, 37 Furthermore, epidemiological studies of mortality and morbidity of PCHD must be consequently revised. Differences in MAPs and PPs could be helpful in the explanation of the 'paradox' of increasing mortality in PCHD with lower BP levels. Additionally, the population of PCHD should not be observed as a single group and differences in medication and intradialysis hypotension occurrence must be considered.
